Neurogene Inc. (NGNE)

↓ Download CSV

CIK 0001404644 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

In fiscal 2025, Neurogene Inc. reported revenue of $0, down 100.0% from the prior year. The company ran a net loss. It held $288.60M in total assets against $23.72M in total liabilities.

Key ratios (FY2025)

-34.1%
Return on equity
-100.0%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$0$925.0K$0$25.00M
Operating Income-$103.33M-$82.61M-$55.58M-$56.52M-$60.70M-$33.73M-$70.96M-$32.62M-$51.12M-$37.65M
Net Income-$90.35M-$75.14M-$36.32M-$55.19M-$60.69M-$33.28M-$69.44M-$31.59M-$50.18M-$37.00M
EPS (Diluted)$-4.24$-4.28$-1.04$-1.10$-0.64
Total Assets$288.60M$335.73M$222.57M$109.27M$163.26M$210.52M$147.02M$77.62M$110.33M$154.38M
Total Liabilities$23.72M$25.36M$36.55M$10.64M$20.40M$19.30M$5.34M$4.95M$11.44M$9.72M
Shareholders' Equity$264.89M$310.38M$186.02M-$145.74M-$91.88M$191.22M$141.69M$72.67M$98.89M$144.66M
Cash & Equivalents$103.84M$136.59M$148.21M$82.02M$142.47M$192.56M$143.09M$76.93M$52.03M$32.30M
Operating Cash Flow-$77.17M-$70.60M-$51.42M-$52.82M-$47.56M-$24.57M-$15.39M-$31.58M-$44.72M-$30.23M
Capital Expenditures$1.18M$808.0K$321.0K$2.23M$3.26M$2.22M$879.0K$49.0K$494.0K$713.0K
Shares Outstanding15.49M14.85M12.82M042.46M42.20M38.00M23.54M23.47M23.42M